�One of the world's longest and largest trials of internal secretion replacement therapy (HRT) has found that post-menopausal women on HRT gain substantial improvements in quality of life.
The results of the latest study by the WISDOM research team (Women's International Study of foresighted Duration Oestrogen after Menopause) are promulgated today on the British Medical Journal website http://www.bmj.com.
The study involved 2130 postmenopausal women in the UK, Australia and New Zealand, and assessed the shock of combined oestrogen and progestogen internal secretion therapy on the women's quality of life. The average geezerhood of women in this study was 13 age after climacteric and most participants did not have menopausal symptoms.
"Our results show that hot flushes, night sweats, sleeplessness and roast pains were less common in women on HRT in this age group. Sexuality was also improved," says Professor Alastair MacLennan, leader of the Australian arm of WISDOM and head of Obstetrics & Gynaecology at the University of Adelaide, Australia.
"Overall, calibre of life measures improved. Even when women did not feature hot flushes and were well past menopause, there was a small only measurable melioration in quality of liveliness and a noted improvement in sleep, sexuality and joint pains. HRT users also had more titty tenderness and discharge compared to those on a placebo," he says.
Dr Beverley Lawton, Head of WISDOM New Zealand, says: "These new information should be added to the risk/benefit equation for HRT. The quality of life benefits of HRT may be greater in women with more grave symptoms near menopause. New research suggests that HRT taken from near climacteric avoids the cardiovascular risks seen when HRT is initiated many years after menopause."
Professor MacLennan says studies such as those conducted by WISDOM "enable the risks of HRT to be rock-bottom and its benefits maximized when the treatment is individualized to each woman".
"Early start-up side effects backside usually be alleviated by adjusting the treatment," he says. "For most women with substantial menopause symptoms the benefits of HRT outweigh the risks. The latest analyses of the main semipermanent randomized control trial of HRT (The Women's Health Initiative) show that chest cancer is not increased by oestrogen-only HRT and is only increased in women exploitation combined oestrogen and progestogen HRT after seven age of usance. This increased risk is less than 0.1% per year of use.
"If a woman feels that HRT is needed for quality of life, then doctors can buoy find the safest regime for her. She can buoy try exit off HRT every xlv years, and can then make an informed pick about whether she takes and continues HRT."
The WISDOM research is independent of the pharmaceutical industry and has been funded by UK, Australian and New Zealand government research bodies.
University of Adelaide
Level 1, 115 Grenfell St.
Adelaide 5005
Australia
http://www.adelaide.edu
More info
